Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 14/20 | 0.54 |
| ▸ | ERBB2 | P04626 | 11/20 | 0.54 |
| ▸ | EPHA2 | P29317 | 3/20 | 0.50 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.49 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.49 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.49 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27148662 | 0.86 | EPHA2 (0.57) | EGFRERBB2EPHA2 | |
| SCHEMBL30820474 | 0.86 | EPHA2 (0.57) | EGFRERBB2EPHA2 | |
| SCHEMBL30032119 | 0.86 | EPHA2 (0.57) | EGFRERBB2EPHA2 | |
| SCHEMBL24715207 | 0.82 | EGFR (0.72) | EGFRERBB2 | |
| SCHEMBL30030486 | 0.82 | EGFR (0.72) | EGFRERBB2 | |
| SCHEMBL3966911 | 0.82 | EGFR (0.77) | EGFRERBB2EPHA2 | |
| SCHEMBL29781269 | 0.82 | EGFR (0.77) | EGFRERBB2EPHA2 | |
| SCHEMBL30031493 | 0.82 | EGFR (0.46) | EGFRERBB2EPHA2 | |
| SCHEMBL27146500 | 0.82 | EGFR (0.46) | EGFRERBB2EPHA2 | |
| SCHEMBL27151913 | 0.80 | EGFR (0.51) | EGFRERBB2EPHA2PIK3CDPIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240246940-A1 | HETEROARYL DERIVATIVE COMPOUND AND USE THEREOF | VORONOI INC. (KR) | 2024-07-25 | — | — | US | disclosed |
| EP-4328222-A1 | HETEROARYL DERIVATIVE COMPOUND AND USE THEREOF | Voronoi Inc. (KR) | 2024-02-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240246940-A1 | HETEROARYL DERIVATIVE COMPOUND AND USE THEREOF | ERBB2, EGFR, ERBB3 | EGFR 2/4885ERBB2 1/4885EPHA2 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.